Blockchain Registration Transaction Record

Brain Delivery Breakthrough: Oncotelic's N2B System Targets Alzheimer's and Biodefense

Oncotelic Therapeutics advances CNS drug delivery with intranasal N2B system for Alzheimer's and biodefense, joining Biogen, Moderna, and CytoDyn in overcoming the blood-brain barrier.

This news matters because it highlights a critical bottleneck in treating brain disorders—the blood-brain barrier. Oncotelic's intranasal delivery system could revolutionize how drugs reach the brain, potentially enabling effective treatments for Alzheimer's, which affects millions worldwide, and enhancing biodefense capabilities. For patients, investors, and the healthcare industry, this innovation represents a shift from drug discovery to solving delivery challenges, unlocking new therapeutic possibilities.